



W:\Virus Research\732250-190\Robert Finberg DECLARATION.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Knipe, et al.
Serial No. : 08/278,601
Filed : July 21, 1994
For : Herpesvirus Replication Defective Mutants
Group : 1645
Examiner : Caputa, A.

Assistant Commissioner of Patents
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. §1.608(b)

I, Robert Finberg, declare:

1. That prior to September 25, 1990, experiments were performed in my laboratory at the Dana Farber Cancer Institute with my knowledge, at the request of and on behalf of David Knipe, a named inventor of the above-captioned application. My curriculum vitae is attached hereto as Appendix A.
2. That the experiments were performed prior to September 25, 1990 by Lien Huong Nguyen who was employed as a post doctorate in my laboratory at the Dana Farber Cancer Institute. Dr. Nguyen is no longer employed by the Dana Farber Cancer Institute.
3. That the following is a factual description of experiments performed by Dr. Nguyen in the United States prior to September 25, 1990.
4. That Dr. Nguyen was requested to perform these experiments by me at David Knipe's request and she performed these experiments with my knowledge.

5. That Appendix B attached hereto are true copies, with dates deleted, of laboratory notebook pages from the notebook of Dr. Nguyen. The notebook was issued by the Dana Farber Cancer Institute and the notebook is still in the possession of the Dana Farber Cancer Institute. The dates deleted from the notebook pages are dates prior to September 25, 1990.

6. That I recognize the handwriting on the notebook pages as the handwriting of Dr. Nguyen.

7. That the notebooks were maintained in conjunction with the performance of the experiments performed by Dr. Nguyen in the United States before September 25, 1990.

8. That based on personal knowledge, Dr. Nguyen demonstrated, in the United States prior to September 25, 1990, that two different mutant herpesviruses protected mice against a lethal dose of wild-type herpesvirus, HSVmP. The mutant herpesviruses that provided such protection were not capable of producing additional virus in cells other than cells that complemented the defective genes. In particular, the mutated viruses used in these experiments consisted of one herpesvirus containing a deletion mutation in the gene that expresses ICP8, known as mutant d301; and the other herpesvirus containing a nonsense insertion mutation in the gene expressing ICP27, known as mutant n504R.

9. That the mutant herpesviruses were obtained from David Knipe with the understanding that my laboratory would perform experiments to demonstrate that such mutant viruses were protective against wild-type herpesvirus.

10. That the experiments performed by Dr. Nguyen in the United States prior to September 25, 1990 were as follows:

10⁶ pfu of replication-defective viruses, those containing mutations in the genes encoding ICP8 or ICP27, were injected into mice, and then challenged with a lethal dose of 10⁸ pfu live wild-type HSV-1 virus. The mice that received the mutants had 100 %

survival rates whereas the control mice that did not receive mutant virus had a 10 % survival rate. Thus the experiments demonstrated that replication defective mutants of

HSV-1 induced immunity in mice injected with the mutant viruses and protected against lethal infection whereas the majority of mice injected with control material and subsequently challenged with wild type virus, died.

11. That the following correlates the above-described experiment to the notebook pages provided in Appendix B:

A. Female Balb/c mice, 5 to 7 weeks of age, were used for the experiment. These mice were injected intraperitoneally with the viruses or control samples.

This is stated on page **HOO3388**:

second line "injection mice with";

third line right side of page near the margin "n=8 Balb";

just below the middle of the page on the right across from the number ②
"n=8Balb mice".

and on page **HOO3497** first and second lines where it is written

"① Balb mice.... ♀. 5-7 weeks by _____."

"n" refers to the number of mice in the group.

B. Viruses used in the experiment were obtained from the laboratory of Dr. David Knipe.

This is stated on page **HOO3388**

top line on the left "All virus received from Dr. David Knipe _____";

fifth line: "ICP8 stock d301 _____ received from Dr. David Knipe's Lab (Kay)
on day _____."

The titer of the viruses was 1.7×10^9 pfu/cc for the ICP8 mutant virus page **HOO3388** 8th line and 4×10^8 pfu for ICP237 (n504R) on line midpage in paragraph ②.

"ICP8" refers to the replication defective mutant virus containing a mutation in the gene encoding ICP8, termed d301; "ICP27" refers to the replication defective mutant virus containing a mutation in the ICP27 gene, termed n504R.

C. The mutant viruses were diluted to 10^6 pfu/cc in an injection volume per mouse of .5cc.

This is shown on page **HOO3388**

par.① 6th line "Need 10^6 pfu/cc. so do a 1:1700 dilution that means :100 λ in 170000 = 170cc or: 100 λ (virus stock) in 85cc PBS and injection of .5cc"

par.② 2nd line "Need 10^6 pfu/cc: So do a 1: 4 10^2 Dilution that means 100 λ in 40000 = 40cc. PBS or 100 λ (virus) in 20cc and inject 0.5cc."

D. Groups of eight mice were injected with 10^6 pfu of each of the replication defective mutants ICP8 (d301) and ICP27 (n504R). Control mice (group of 9 mice) were injected with PBS.

This is shown on page **HOO3388**

third line right side of page near the margin "n=8 Balb";

just below the middle of the page on the right across from the number ②
"n=8Balb mice".

and on page **HOO3497**

par. ① "Balb mice.... ♀. 5-7 weeks by _____."

" _____ : challenged with

106pfu HSV ICP8 n=8 (2)

106pfu HSV ICP27 n=8 (3)

and n=9 (4)

PBS as control"

E. Six weeks plus 5 days later, all the mice were challenged with 10^8 pfu of a virulent wild-type HSV-1 strain , HSV-1 (mP).

This is shown on notebook page **HOO3497**:

mid page: "Date deleted : challenge with 10^8 pfu HSV-mP."

F. Mortality was determined 10 days post challenge with HSV-1mP. As reported on notebook page HOO3487, two mice each from the groups injected with mutant virus were removed for proliferation assay studies leaving six mice per group. The mice which had been inoculated with the mutants ICP8 (d301) or ICP27 (n504), 0 (zero) mice of six died; 1/9 control (PBS injected) mice survived, that is 8 out 9 mice died.

This is shown on the bottom half of page **HOO3497** as follows:



"Mortality:

in 10 days

(2)	(ICP8)	0 died.
(3)	(ICP27)	0 died.
(4)	8 died from 9.	(control)"

12. That I hereby declare that all statements made herein are true, and all statements made on information and belief are believed to be true, and further that all statements were made with the knowledge that any willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issued thereon.

Date: _____



Robert Finberg

CURRICULUM VITAE

Name: Robert William Finberg
Address: 48 Spring Lane, Canton, Massachusetts 02021
Place of Birth: Baltimore, Maryland

Education:

1971 A.B. University of Chicago
 1974 M.D. Albert Einstein College of Medicine
 1996 M.A. (Hon.) Harvard University

Postdoctoral Training:**Internship and Residencies:**

1974-1975 Intern in Medicine, Bellevue Hospital, New York
 1975-1976 Junior Resident in Medicine, Bellevue Hospital
 1976-1977 Senior Resident in Medicine, Bellevue Hospital
 1979-1980 Fourth Year Resident Physician, Peter Bent Brigham Hospital, Boston, MA

Clinical and Research Fellowships:

1977-1978 Research Fellow in Pathology, Harvard Medical School, Boston, MA
 1978-1979 Research Fellow in Medicine, Harvard Medical School
 1978-1979 Research/Clinical Fellow in Medicine, Peter Bent Brigham Hospital
 1979-1980 Clinical Fellow in Medicine, Harvard Medical School

Licensure and Certification:

1976 Massachusetts License Registration No. 40199
 1976 American Board of Internal Medicine, Candidate No. 058714
 1980 Board Certified - Infectious Diseases, Candidate No. 058714

Academic Appointments:

1980-1984 Assistant Professor of Medicine, Harvard Medical School
 1985-1995 Associate Professor of Medicine, Harvard Medical School
 1996-Present Professor of Medicine, Harvard Medical School

Hospital Appointments:

1980-1982	Junior Associate in Medicine, Brigham & Women's Hospital, Boston, MA
1980-1984	Assistant Physician, Chief of Infectious Diseases, Dana-Farber Cancer Institute, Boston, MA
1982-	Associate Physician, Brigham & Women's Hospital
1985-1986	Courtesy Staff, The Children's Hospital, Boston, MA
1985-1992	Associate Physician, Chief of Infectious Diseases, Dana-Farber Cancer Institute
1986-	Staff Physician, The Children's Hospital
1992-1995	Associate Professor of Medicine, Chief of Infectious Diseases, Dana-Farber Cancer Institute
1996-Present	Professor of Medicine, Chief of Infectious Diseases, Dana-Farber Cancer Institute

Awards and Honors:

1973	Alpha Omega Alpha
1980-1983	Hartford Foundation Award for the support of faculty in scientific research
1983-1988	Scholar of the Leukemia Society

Major Committee Assignments:

Government:

1984	Special Reviewer, Experimental Immunology Study Section
1985-1989	Regular Reviewer, Experimental Immunology Study Section
1990-1995	Secretarial appointee, Department of Veterans Affairs, Medical Research Service, Career Development Committee
1991-1994	AIDS and Special Virology and Vaccines Ad Hoc Committees
1995-7	Special Reviewer, Immunobiology Study Section

Harvard Medical School, Graduate Student Supervision:

1980-	Member, Committee on Virology
1983-	Member, Committee on Immunology

Memberships in Professional Societies:

1974-	American Association for the Advancement of Science
1978-	American Society of Microbiology
1979-	American Association of Immunologists
1979-	American College of Physicians
1980-	American Federation for Clinical Research
1982-	Infectious Disease Society of America, Fellow
1985-	American Society for Clinical Investigation
1987-	Pediatric Infectious Disease Society
1988-	Clinical Immunological Society
1992-	Immunocompromised Host Society

Editorial Boards:

1982-1985	Infection and Immunity
1982-1995	Infectious Disease Practice
1984-	Journal of Immunology
1984-	Survey of Immunologic Research

Major Research and Clinical Interests:

1. The importance of T cells in mammalian responses to viruses
2. The regulatory role of T cells in response to bacterial infections
3. GPI-Anchored Proteins as Signal transduction molecules
4. HIV-1 - CD4 interactions
5. Picornavirus receptors
6. Infections in immunocompromised patients

Research Funding Information

Active

1992-2000	NIH, RO1AI31628	PI	Cell Surface Proteins Involved in Echovirus Attachment
1995-1998	NIH PO1 A137963-01	Co-PI	Mechanisms Involved in the Generation of Protective Immunity
1989-1999	NIH 2P30 AI28691-06	Co-PI	AIDS Center Support Grant
1997-2002	NIH, RO1 AI 39576-01	Co-PI	Pathogenic Mechanisms of Anaerobes in Sepsis
1995-1998	IDF International: Juvenile Diabetes	PI	A Virus Induced Autoimmune Disease
1998-2001	Novartis Drug Discovery Program	PI	Role of Bcl-2/x viral homologues in epithelial malignancies

Expired

1996-1997	Aroncx: A randomized trial of liposomal nystatin versus amphotericin B	PI	
1994-1996	Fujisawa: A randomized trial of Ambisome versus amphotericin B	PI	
1995-1996	Omnibus Solicitation: PHS SBIR, PHS 95-3	PI	Virus Inactivation in Blood Using Microwave Heating
1995-1996	Women's Breast Cancer Program	PI	G Proteins and GPI-Anchored Surface Proteins in Tumor Cells
1995-1997	Fujisawa, USA	PI	Trial: Ambisome vs. Amphotericin B

1992-1996	NIH, P01 A133087 Co-PI Clinical and Laboratory Studies of PID
1994-1995	DFCI Drug Discovery Program PI D2: A Signal Transducing Molecule Present on Tumor Cells
1994-1995	Barr Program Small Grants PI Characterization of Receptor Proteins for Diabetogenic Viruses
1991-1994	NIH, NO1-DE-12585 (subcontract) Co-PI Role of Mononuclear Phagocytes in Opportunistic Infections of Oral Mucosa and Other Tissues in AIDS Patients
1992-1993	Seragen, Inc. PI IL-2 toxin and immune responses
1992-1995	American Heart Association #92013820 PI Cell Surface Proteins Involved in Echovirus Attachment
1983-1993	NIH, RO1CA3479 PI Animal Models of AIDS
1982-1993	NIH, RO1AI20382 PI Cell Mediated Immune Response to Murine Viruses
1990-1993	NIH 1R01AI29657-02 Opioids and Opiates: T Cell Motility
1989-1990	Massachusetts Mutual Life Insurance Company PI A Study on the Measurement of Immune Responses to the AIDS Virus in Children
1987-1990	DAMD-87-C-7151 PI Analysis of the Human T cell Response to HTLV-III
1990-1991	DFCI Center for AIDS Research PI Resistance of Human T Cells to HIV-1 Infection
1989-1990	Seragen, Inc. PI Effects of IL-2 Toxin on HIV-1 Infection of Cells
1990-1991	Seragen, Inc. PI Use of DAB486 IL-2 to Eliminate HIV-1 Infected Cells
1990-1991	DFCI Center for AIDS Research PI CPE: An HIV-1 Binding Peptide
1984-1989	5R01 AI20541 PI Immune Regulation by Cytotoxic T Cell Clones
1983-1988	LSA Scholar PI Use of T Cell Hybridomas in Infection
1986-1987	AmFAR, Grant No. 00104 PI Analysis of T-Cell Responses to AIDS

1985-1987 Sero Laboratories PI
 Effect of Thymic-derived Lymphokines on T Cell Responses and
 Infections in Bone Marrow Transplant Patients

1985-1986 Whitaker Foundation PI
 Cloning and Genomic Analysis of a Receptor Molecular from an Ag
 Specific T Cell Hybridoma

1983-1985 Biogen, Inc. PI
 Investigation of T cells in Patients with AIDS

1980-1985 Hartford Foundation PI
 Award for Junior Faculty

1980-1992 NIH, 5R01 AI20382 PI
 Cell Mediated Immune Response to Murine Viruses

Pending

1998-2003 NIH, R01 GM57520 PI
 LPS Mediated Endotoxic Shock: Mechanisms of Pathogenesis

1997-1999 Pfizer, Inc
 A randomised trial of Voriconazole versus amphotericin B PI

Principal Clinical and Hospital Service Responsibilities:

1980- Attending in Medicine and Infectious Diseases, Brigham & Women's
 Hospital

1980- Consultant in Infectious Diseases, Children's Hospital, Boston, MA

1982- Chief, Infectious Diseases, Dana-Farber Cancer Institute

Teaching Experience:

Classroom:

1980, 83-84 Pathophysiology 902 conference leader, Harvard Medical School

1981-1982 Immunology 700 lecturer, Harvard Medical School

1986 Tutor, New Pathway, Harvard Medical School

1987 Lecturer, Immunobiology 204, Harvard School of Public Health,
 Boston, MA

1987-1990 Tutor, Identify and Defense, New Pathway, Harvard Medical School

1990-1992 Case Coordinator for Immunology and Microbiology,
 Harvard Medical School

1991-1992 Lecturer, Virology 314, Harvard Medical School

1991- Member, Advanced Basic Science Committee

1993- Senior Fellow for ABS, Harvard Medical School

1992- Modern Medical Microbe Hunters (IN505.J), course director

1992- Interactions of Viruses with Mamalian Cells (ME551.5) , course director

Clinical:

1980-1981	Consult visit in Infectious Disease, Brigham & Women's Hospital
1981-	Consult visit in Infectious Disease, Dana-Farber Cancer Institute
1981-	Ward visit in Medicine, Brigham & Women's Hospital
1983-	Consult visit in Infectious Disease, The Children's Hospital

BIBLIOGRAPHY

Original Reports:

1. Finberg R, Barland P, Grayzel AI. Measurement of complement components in systemic lupus erythematosus by radial immunodiffusion. *Am J Clin Pathol.* 1977;67:97-9.
2. Burakoff SJ, Finberg R, Glimcher L, Lemonnier F, Benacerraf B, Cantor H. The biologic significance of alloreactivity. The ontogeny of T-cell sets specific for alloantigens or modified self antigens. *J Exp Med.* 1978;148:1414-22.
3. Finberg R, Mescher M, Burakoff SJ. The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. *J Exp Med.* 1978;148:1620-7.
4. Finberg R, Burakoff SJ, Cantor H, Benacerraf B. Biological significance of alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse allogeneic target cells. *Proc Natl Acad Sci USA.* 1978;75:5145-9.
5. Finberg R, Weiner HL, Fields BN, Benacerraf B, Burakoff SJ. Generation of cytolytic T lymphocytes after reovirus infection: role of *S1* gene. *Proc Natl Acad Sci USA.* 1979;76:442-6.
6. Finberg R, Greene MI, Benacerraf B, Burakoff SJ. The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. I. Evidence for antigen-specific helper T cells. *J Immunol.* 1979;123:1205-9.
7. Finberg R, Burakoff SJ, Benacerraf B, Greene MI. The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. II. Evidence for antigen-specific suppressor T cells. *J Immunol.* 1979; 123:1210-4.
8. Finberg R, Cantor H, Benacerraf B, Burakoff S. The origins of alloreactivity: differentiation of prekiller cells to viral infection results in alloreactive cytolytic T lymphocytes. *J Immunol.* 1980;124(4):1858-60.
9. Burakoff SJ, Reiss CS, Finberg R, Mescher MF. Cell-mediated immunity to viral glycoproteins. *Rev Infec Dis.* 1980;2(1):62-78.
10. Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN. Intestinal M cells: a pathway for entry of reovirus into the host. *Science.* 1981;212:471-2.
11. Finberg R, Weiner HL, Burakoff SJ, Fields BN. Type-specific reovirus antiserum blocks the cytotoxic T-cell-target cell interaction: evidence for the association of the viral hemagglutinin of a nonenveloped virus with the cell surface. *Infect Immun.* 1981;31:646-9.
12. Letvin NL, Kauffman RS, Finberg R. T lymphocyte immunity to reovirus: cellular requirements for generation and role in clearance of primary infections. *J Immunol.* 1981; 127(6):2334-9.
13. Shapiro ME, Burakoff SJ, Benacerraf B, Finberg RW. *Ir* gene control of the cytotoxic T lymphocyte response to Sendai virus: H-2^k mice are low responders to Sendai. *J Immunol.* :2571-4.
14. Finberg R, Benacerraf B. Induction, control and consequences of virus specific cytotoxic T cells. *Immunol Rev.* 1981;58:157-80.

15. Takaoki M, Sy M-S, Whitaker B, Nepom J, Finberg R, Germain RN, Nisonoff A, Benacerraf B, Greene MI. Biologic activity of an idiotype-bearing suppressor T cell factor produced by a long-term T cell hybridoma. *J Immunol.* 1982;128(1):49-53.
16. Greene MI, Ratnofsky S, Takaoki M, Sy MS, Burakoff S, Finberg RW. Antigen-specific suppression of cytotoxic T cell responses: an idiotype-bearing factor regulates the cytotoxic T cell response to azobenzenearsonate-coupled cells. *J Immunol.* 1982;128:1188-91.
17. Shapiro ME, Onderdonk AB, Kasper DL, Finberg RW. Cellular immunity to *Bacteroides fragilis* capsular polysaccharide. *J Exp Med.* 1982;155:1188-97.
18. Whitaker RB, Kauffman RS, Che M, Finberg R. CT hybridomas: tumor cells capable of lysing virally infected target cells. *J Immunol.* 1982;129:900-3.
19. Sy M-S, Lee SH, Tsurufuji M, Rock KL, Benacerraf B, Finberg R. Two distinct mechanisms regulate the *in vivo* generation of cytotoxic T cells. *J Exp Med.* 1982;156:918-23.
20. Finberg R, Spriggs DR, Fields BN. Host immune response to reovirus: CTL recognize the major neutralization domain of the viral hemagglutinin. *J Immunol.* 1982;129:2235-8.
21. Takaoki M, Sy M-S, Tominaga A, Lowy A, Tsurufuji M, Finberg R, Benacerraf B, Greene MI. I-J restricted interactions in the generation of azobenzenearsonate-specific suppressor T cells. *J Exp Med.* 1982;156:1325-34.
22. Letvin NL, Kauffman RS, Finberg R. An adherent cell lyses virus-infected targets: characterization, activation, and fine specificity of the cytotoxic cell. *J Immunol.* 1982;129(6):2396-401.
23. Ertl HCJ, Greene MI, Noseworthy JH, Fields BN, Nepom JT, Spriggs DR, Finberg RW. Identification of idiotypic receptors on reovirus-specific cytolytic T cells. *Proc Natl Acad Sci. USA.* 1982;79:7479-83.
24. Onderdonk AB, Kasper DL, Shapiro ME, Finberg RW. Role of the capsular polysaccharide of *Bacteroides fragilis* in pathogenicity. *Microbiology.* 1982;335-7.
25. Ertl HCJ, Brown EG, Finberg RW. Sendai virus-specific T cell clones. II. Induction of interferon production by Sendai virus-specific T helper cell clones. *Eur J Immunol.* 1982;12:1051-3.
26. Shapiro ME, Onderdonk AB, Kasper DL, Finberg RW. Immune T cells prevent *Bacteroides fragilis* abscesses. *Curr Surg.* 1983;40:123-6.
27. Kauffman RS, Wolf JL, Finberg R, Trier JS, Fields BN. The sigma 1 protein determines the extent of spread of reovirus from the gastrointestinal tract of mice. *Virology* 1983;124:403-10.
28. Wolf JL, Kauffman RS, Finberg R, Dambrauskas R, Fields BN, Trier JS. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. *Gastroenterology.* 1983;85:291-300.
29. Sy M-S, Tsurufuji M, Finberg R, Benacerraf B. Effect of vesicular stomatitis virus (VSV) infection on the development and regulation of T cell-mediated immune response. *J Immunol.*
30. Kauffman RS, Noseworthy JH, Nepom JT, Finberg R, Fields BN, Greene MI. Cell receptors for the mammalian reovirus. II. Monoclonal anti-idiotypic antibody blocks viral binding to cells. *J Immunol.* 1983;131:2539-41.

31. Kauffman RS, Lee S, Finberg R. Cytolytic T-cell mediated lysis of reovirus-infected cells: requirements for infectious virus, viral particles, and viral proteins in infected target cells. *Virology*. 1983;131:265-73.
32. Scott CF Jr., Tsurufuji M, Lu CY, Finberg R, Sy M-S. Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. *J Immunol*. 1984;132:633-9.
33. Finberg R. Recent developments in immunovirology. *Surv Immunol Res*. 1984;3:233-7.
34. Ertl HCJ, Finberg RW. Characteristics and functions of Sendai virus-specific T-cell clones. *J Virol*. 1984;50:425-31.
35. Ertl HCJ, Finberg RW. Sendai virus-specific T-cell clones: induction of cytolytic T cells by an anti-idiotypic antibody directed against a helper T-cell clone. *Proc Natl Acad Sci USA*. 1984;81:2850-4.
36. Letvin NL, Hunt RD, Finberg R. Animal models of AIDS. *Semin Oncol*. 1984;11:18-28.
37. Ertl HCJ, Homans E, Tournas S, Finberg RW. Sendai virus-specific T cell clones. V. Induction of a virus-specific response by antiidiotypic antibodies directed against a T helper cell clone. *J Exp Med*. 1984;159:1778-83.
38. Epstein RL, Finberg R, Powers ML, Weiner HL. Interaction of reovirus with cell surface receptors. IV. The reovirus type 3 receptor is expressed predominantly on murine Lyt-2,3⁺ and human T8⁺ cells. *J Immunol*. 1984;133(3):1614-7.
39. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. *Lancet*. 1984;2:427-31.
40. Heagy W, Kelley VE, Strom TB, Mayer K, Shapiro HM, Mandel R, Finberg R. Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. *J Clin Invest* 1984;74:2089-96.
41. Onderdonk AB, Shapiro ME, Finberg RW, Zaleznik DF, Kasper DL. Use of a model of intraabdominal sepsis for studies of the pathogenicity of *Bacteroides fragilis*. *Rev Infect Dis*. 1984;6:S91-5.
42. Groopman JE, Mayer KH, Sarngadharan MG, Ayotte D, Devico AL, Finberg R, Sliski AH, Allan JD, Gallo RC. Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and asymptomatic controls in Boston. *Ann Intern Med*. 1985;102:334-7.
43. Sharpe AH, Gaulton GN, Ertl HCJ, Finberg RW, McDade KK, Fields BN, Greene MI. Cell receptors for the mammalian reovirus. IV. Reovirus-specific cytolytic T cell lines that have idiotypic receptors recognize anti-idiotypic B cell hybridomas. *J Immunol*. 1985;134:2702-6.
44. Zaleznik DF, Finberg RW, Shapiro ME, Onderdonk AB, Kasper DL. A soluble suppressor T cell factor protects against experimental intraabdominal abscesses. *J Clin Invest*. 1985;75:1023-7.
45. Finberg RW, Ertl HCJ. Use of T-cell specific anti-idiotypes to immunize against viral infections. *Immunol Rev*. 1986; 90:129-155.
46. Pennington JE, Groopman JE, Small GJ, Laubenstein L, Finberg R. Effect of intravenous recombinant gamma-interferon on the respiratory burst of blood monocytes from patients with AIDS. *J Infect Dis*. 1986;153(3):609-12.

47. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gorgone B, Antman K, Anderson J, Anderson K, Kruskall MS, Schnipper L, Frei E III: High-dose combination alkylating agents with autologous bone marrow support: a Phase I trial. *J Clin Oncol.* 1986;4:646-54.
48. Ertl HCJ, Skinner MA, Finberg RW. Induction of anti-viral immunity by an anti-idiotypic antibody directed to a Sendai virus specific T helper cell clone. *Intern Rev Immun.* 1986;1:41-65.
49. Shapiro ME, Kasper DL, Zaleznik DF, Spriggs S, Onderdonk AB, Finberg RW. Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to *Bacteroides fragilis*. *J Immunol.* 1986;137:341-6.
50. Skinner MA, Finberg RW, Ertl HCJ. Regulation of cytotoxic lymphocyte precursors. II. The effect of interleukin-2 and interferon-gamma on the apparent specificity of effector cells. *Cell Immunol.* 1986;100:239-46.
51. Antman K, Eder JP, Schryber S, Andersen J, Peters WP, Henner WD, Elias A., Shea T, Finberg RW, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast R, Schnipper L, Frei E, III. A high dose combination alkylating agent preparative regimen with autologous bone marrow support: The DFCI/BIH experience. *J Clin Oncol.* 1986;4:646-84.
52. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Gorgone B, Bast R, Schnipper L, Frei E, III, and the Solid Tumor Autologous Bone Marrow Team. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. *Cancer Treat.Rep.* 1987; 71:119-25.
53. Ambrosino DM, Siber GR, Chiltonczyk BA, Jernberg JB, Finberg RW. An immunodeficiency characterized by impaired antibody responses to polysaccharides. *N Engl J Med.* 1987;316:790-3.
54. Skinner M, Ertl HCJ, Finberg RW. Lymphokines induce specificity degradation in virus-induced cytolytic T-cell clones. *Cell Immunol.* 1987;109:159-68.
55. Crumpacker C, Heagy W, Bubley G, Monroe JE, Finberg R, Hussey S, Schnipper L, Lucey D, Lee TH, McLane MF, Mulder C, Essex M. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase I study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. *Ann Intern Med.* 1987; 107:664-74.
56. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. *J Natl Cancer Inst.* 1988;80:1221-6.
57. Cohen JJ, Deresiewicz RL, Finberg RW. Fever, hypotension, and pulmonary infiltrates in a young Haitian man [clinical conference.] *Rev Infect Dis.* 1988;10:1052-60.
58. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. *Arch Intern Med.* 1988;148:2561-8.
59. Hsu H-W, Finberg RW. Infections associated with animal exposure in two infants [clinical conference.] *Rev Infect Dis.* 1989;11:108-15.
60. Haregewoin A, Soman G, Hom RC, Finberg RW. Human gd+ T cells respond to mycobacterial heat-shock protein. *Nature.* 1989;340:309-12.

61. Onderdonk AB, Cisneros RL, Crabb JH, Finberg RW, Kasper DL. Intraperitoneal host cellular responses and *in vivo* killing of *Bacteroides fragilis* in a bacterial containment chamber. *Infect Immun.* 1989;57:3030-7.
62. Hom RC, Soman G, Finberg R. Trojan horse lymphocytes : a vesicular stomatitis virus specific T cell clone lyses target cells by carrying virus. *J Virol.* 1989;63:4157-64.
63. Heagy W, Strom TB, Kelley VE, Collela J, Crumpacker C, Williams JM, Shapiro HM, Laubenstein L, Finberg R. Recombinant human IFN-g enhances *in vitro* activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome. *Infect Immun.* 1989;57:3619-28.
64. Kasper DL, Finberg RW, Crabb J, Onderdonk AB. Immune mechanisms in the prevention of intraabdominal abscess formation. *Scand. J Infect Dis Suppl.* 1989;62:29-34.
65. Ruprecht RM, Mullaney S, Gama Sosa M, Hom R, Finberg R. Anti-viral therapy induces T cells which protect against viral challenge. *NYAS.* 1989;567:344-6.
66. Heagy, W, M Lurance, E Cohen, and R Finberg. Neurohormones regulate T cell function. *J Exp Med.* 1990;171:1625-33.
67. Heagy W, Groopman J, Schindler J, Finberg R. Use of IFN-g in patients with AIDS. *J Acquir Immune Defic Syndr.* 1990;3:584-90.
68. Diamond DC, Finberg R, Chaudhuri S, Sleckman BP, Burakoff SJ. Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4. *Proc Natl Acad Sci. USA.* 1990;87:5001-5.
69. Crabb JH, Finberg R, Onderdonk AB, Kasper DL. T cell regulation of *Bacteroides fragilis*-induced intraabdominal abscesses. *Rev Infect Dis.* 1990;12:S178-84.
70. Onderdonk AB, Cisneros RL, Finberg R, Crabb JH, Kasper DL. Animal model system for studying virulence of and host response to *Bacteroides fragilis*. *Rev Infect Dis* 1990;12:S169-77.
71. Ruprecht RM, Mullaney S, Bernard LD, Gama-Sosa MA, Hom RC, Finberg RW. Vaccination with a live retrovirus: the nature of the protective immune response. *Proc Natl Acad Sci. USA.* 1990;87:5558-62.
72. Finberg RW, Diamond DC, Mitchell DB, Rosenstein Y, Soman G, Norman TC, Schreiber SL, Burakoff SJ. Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120. *Science.* 1990; 249:287-91.
73. Hom RC, Finberg RW, Mullaney S, Ruprecht RM. Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells. *J Virol* 1991;61:220-4.
74. Ambrosino DM, Kanchana MV, Delaney NR, Finberg RW. Human B cells secrete predominantly 1 light chains in the absence of heavy chain expression. *J Immunol.* 1991;146:599-602.
75. Haregewoin A, Singh B, Gupta RS, Finberg RW. A mycobacterial heat shock protein responsive gd T cell clone also responds to the homologous human heat shock protein. *J Infect Dis.* 1991;163:156-60.
76. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. *Transplantation.* 1991; 51:630-6.

77. Robertson MJ, Socinski MA, Soiffer RJ, Finberg RW, Wilson C, Anderson KC, Bosserman L, Sang D, Salkin IF, Ritz J. Successful treatment of disseminated fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia [case report]. *Bone Marrow Transplantation*. 1991; 8(2):144-5.
78. Silberman SL, Goldman SJ, Mitchell D, Tong A, Rosenstein Y, Diamond D, Finberg R, Schreiber S, Burakoff SJ. The interaction of CD4 with HIV-1 gp120. *Seminars in Immunology*. 1991;3:187-92.
79. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. *J Clin Invest*. 1991; 87:1916-24. .
80. Heagy W, Groopman J, Schindler J, Finberg R. IFN-g to treat patients with AIDS. *J Acquir Immune Defic Syndr*. 1991;4:297-303.
81. Soman G, Haregewoin A, Hom RC, Finberg RW. Guanidine group specific ADP-ribosyltransferase in murine cells. *Biochem Biophys Res Comm*. 1991;176:301-8.
82. Finberg RW, Wahl SM, Allen JB, Soman G, Strom TB, Murphy JR, Nichols JC. Selective elimination of HIV-1 infected cells using an IL-2 receptor specific cytotoxin. *Science*. 1991;252:1703-5.
83. Haregewoin A, Hom RC, Soman G, Finberg RW. Murine T cell hybridoma-derived products regulate the growth of skeletal muscle myoblasts. *Lymphokine and Cytokine Research*. 1991;10(5):391-6.
84. Talcott JA, Siegel RD, Finberg RW, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two center validation of a prediction rule. *J Clin Onc*. 1992;10(2):316-22.
85. Finberg RW, Newburger JW, M.P.H., Mikati MA, Heller AH, Burns JC. Effect of high doses of intravenous gammaglobulin on natural killer cell activity in peripheral blood. *J Peds*. 1992; 120(3):376-80.
86. Bergelson JM, Shepley MP, Chan BMC, Hemler ME, Finberg RW. Identification of the integrin VLA-2 as a receptor for echovirus 1. *Science*. 1992;255:1718-20.
87. Marshall WL, Diamond DC, Kowalski MM, Finberg RW. High level of surface CD4 prevents stable HIV infection of T cell transfectants. *J Virol*. 1992; 66:5492-9.
88. Finberg RW, White W, Nicholson-Weller A. DAF expression on either effector or target cells inhibits cytotoxicity by human NK cells. *J Immunol*. 1992; 149:2055-60.
89. Heagy W, Shipp M, Finberg RW. Opioid Receptors and Ca²⁺ Modulation in Human B Cell Lines. *J Immunol*. 1992;149:4074-81.
90. Ambrosino DM, Bolon D, Collard H, Van Etten R, Kanchana MV, Finberg RW. Effect of *Haemophilus influenzae* polysaccharide outer membrane protein complex conjugate vaccine on Macrophages. *J Immunol*. 1992;149:3978-83.
91. Nguyen LH, Knipe D, Finberg RW. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. *J Virol* 1992;66:7067-72.
92. Weller PH, Rand TH, Barrett T, Elovic A, Wong DTW, Finberg RW. Accessory cell function of human eosinophils: HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1a expression. *J Immunol*. 1993;150:2554-62.

93. Bergelson JM, Chan BMC, Finberg RW, Hemler ME. The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms. *J Clin Invest* 1993;92:232-239.
94. Bergelson JM, St. John N, Kawaguchi S, Chan M, Stubdal H, Modlin J, Finberg RW. Infection by Echoviruses 1 and 8 depends on the α subunit of human VLA-2. *J Virol* 1993;67(11):6847-6852.
95. Talcott JA, Whalen SMA, Clark J, Rieker PP, Finberg R. Home Antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. *J Clin Oncol* 1994;12:107-114.
96. Nguyen L, Knipe DM, Finberg RW. Mechanism of virus-induced subclass shifts. *J Immunol* 1994;152:478-484.
97. Guinan EC, Molrine DC, Antin JH, Lee MC, Weinstein HJ, Sallan SE, Parsons SK, Wheeler C, Gross W, McGarigle C, Blanding P, Schiffman G, Finberg RW, Siber GR, Bolon D, Wang M, Cariati S, and Ambrosino DM. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. *Transplantation* 1994;57:677-684.
98. Ambrosino D, Wang M, Ciamarra A, Chan M, Bolon DL, Minn J, Jacobsohn DA, Finberg RW. T Cells and Natural Killer Cells Regulate Human IgG Subclass Concentration in SCID mice. *Cellular Immunology* 1994;155:134-143.
99. Edelman JM, Chan BMC, Uniyal S, Onodera H, Wang DZ, Damjanovich L, Latzer DB, Finberg RW, Bergelson JM. The mouse VLA-2 homologue supports collagen and laminin adhesion but not virus binding. *Cell Adhesion and Communication* 1994;2:131-143.
100. Marshall WL, Mittler ES, Avery P, Lawrence J, Finberg RW. Glycosylphosphatidylinositol-anchored CD4 supports HIV-1 replication, but not cytopathic effect, in T cell transfectants. *J Virol* 1994;68:4039-4042.
101. Deresiewicz RL, Flaxenburg JA, Chan M, Finberg RW, and Kasper DL. Intracellular expression of toxic shock syndrome toxin 1 in *saccharomyces cerevisiae*. *Infection and Immunity* 1994;62:2202-2207.
102. Hargewoin A, Solomon K, Hom RC, Gopalan S, Bergelson JM, Bhan AK, Finberg RW. Cellular expression of a GPI linked T cell activation protein. *Cellular Immunology* 1994;156:357-370.
103. Bergelson JM, Chan M, Solomon K, St. John NF, Lin H, Finberg RW. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for many echoviruses. *Proc Nat Acad Sci USA* 1994;91:6245-6248.
104. Kawaguchi S, Bergelson JM, Finberg RW, Hemler ME. Integrin α^2 cytoplasmic domain deletion effects: loss of adhesive activity parallels ligand-independent recruitment into focal adhesions. *Molecular Biology of the Cell* 1994;5:977-988.
105. Deresiewicz RL, Woo JH, Chan M, Finberg RW, Kasper DL. Mutations affecting the activity of toxic shock syndrome toxin-1. *Biochem* 1994, 33(43):12844-51.
106. Hargewoin A., Edwin, C, Hom RC, Finberg RW. A 21-mer synthetic peptide of toxic shock syndrome toxin 1, TSST-1 (58-78), activates T cells by binding to MHC class II and by an MHC unrestricted xenostimulatory pathway. *Imm. Invest.* 1994;23 (6-7):413-420.

107. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazol for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. *J Clin Onc* 1995;13(1):239-250.
108. Bergelson JM, St. John NF, Kawaguchi S, Pasqualini R, Berdichevsky F, Hemler ME, Finberg RW. The I domain is essential for echovirus 1 interaction with VLA-2. *Cell Adhesion and communication* 1994;2:455-464.
109. Bergelson JM, Mohanty JG, Crowell RL, St. John NF, Lublin DM, Finberg RW. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). *J Virol* 1995;69(3):1903-1906.
110. King SL, Cunningham JA, Finberg RW, Bergelson JM. Echovirus 1 interaction with the isolated VLA-2 I domain. *J Virol* 1995;69(5):3237-3239.
111. Solomon KR, Chan M, Finberg RW. Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56⁺CD3⁺ lymphocytes (NK cells). *Cell Immunol* 1995;165(2):294-301.
112. Weller PF, Marshall WL, Lucey DR, Rand TH, Dvorak AM, Finberg RW. Infection, apoptosis and killing of mature human eosinophils by human immunodeficiency virus-1. *Am J Resp Cell & Mol Biol* 1995;13(5):610-20.
113. Heagy W, Duca K, Finberg RW. Enkaphalins stimulate leukemia cell migration and surface expression of CD9. *J Clin Invest* 1995;96(3):1366-74.
114. Webb IJ, Coral FS, Anderson JW, Elias AD, Finberg RW, Nadler LM, Ritz J, Anderson KC. Sources and sequelae of bacterial contamination of hematopoietic stem cell products: Implications for safety of hematotherapy and graft engineering. *Transfusion* 1996;36:782-788.
115. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II) Clinical and Experimental Immunology. 103: 408-13, 1996.
116. Brubaker JO, Thompson CM, Morrison LA, Knipe DM, Siber GR, Finberg RW. Th1-associated immune responses to b-galactosidase expressed by a replication-defective herpes simplex virus. *J. Immunol* 1996;157:1598-1604.
117. Solomon KR, Rudd C, Finberg RW. The association between GPI-anchored proteins and heterotrimeric G protein subunits in lymphocytes. *PNAS* 1996;93:6053-6058.
118. Dezube BJ, Ahlers CM, Lawrence JP, Teng ET, Silberman SL, Pardee AB, Finberg RW. Tenidap Inhibits Replication of the Human Immunodeficiency virus-1 in Cultured Cells. *JAIDS* 1997; 14:13-17.
119. Bergelson JM, Cunningham GD, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. *Science* 1997; 275:1320-1323.
120. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. *Journal of Infectious Diseases* 1997, 175:697-700.
121. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW. The murine CAR homologue (mCAR) is a receptor for coxsackie B viruses and adenoviruses. *Journal of Virology*, 1998; 72:415-419.

122. Guttormsen H-K, Wetsler LM, Finberg RW and Kasper DL. Immunologic Memory Induced by a Glycoconjugate Vaccine in a Murine Adoptive Lymphocyte Transfer Model. *Infection and Immunity* 1998; 66(5):2026-2032.
123. Frey BM, Hackett NR, Bergelson JM, Finberg R, Crystal RG, Moore MA, Rafii S. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors.

Reviews:

1. Finberg RW. Cat scratch disease. *Infectious Disease Practice*. 1981; 4:1-7.
2. Finberg R, HCJ, Shapiro ME. Virus-specific cytolytic cells. Their *in vivo* function. *Surv Immunol Res*. 1982; 1:248-54.
3. Finberg RW. Kawasaki disease. *Infectious Disease Practice*. 1982; 5:1-7.
4. Finberg RW. Toxic shock syndrome. *Infectious Disease Practice*. 1983; 6(4):1-5.
5. Finberg RW. Acquired immunodeficiency syndrome infection. *Infectious Disease Practice*. 1983; 6:1-7.
6. Finberg RW. T and B cells in infectious disease. *Infectious Disease Practice*. 1983; 7(2):1-7.
7. Finberg RW. Recent developments in immunovirology. *Surv Immunol Res*. 1984; 3:233-7.
8. Finberg, RW. New approaches to immunization against infectious agents. Use of anti-idiotypes. *Year Immunol*. 1985; 1:175-81.
9. Finberg R, Hom R. The role of T cell immunity in infection with the herpes group viruses. *Year Immunol*. 1986; 2:267-78.
10. Finberg RW, Ertl HCJ. The use of anti-idiotypic antibodies as vaccines against infectious agents. *CRC Crit Rev Immunol*. 1987; 7:269-84.
11. Bergelson J, Finberg RW. Regulation of the T cell receptor genes: the beginnings of the evidence. *Year Immunol*. 1988; 3:53-61.
12. Finberg RW. Immunology of infection. *Immunology and Allergy Clinics of North America*. April 1988; 8(1):137-45.
13. Finberg RW. New concepts in the interaction between T cells and bacteria. *Survey of Immunologic Research*. 1989; 6:140-51.
14. Bergelson J and Finberg R. Integrins as receptors for virus attachment and cell entry. *Trends in Microbiology* 1993;1(8):287-288.

Book Chapters:

1. Mescher M, Finberg RW, Sherman L, Burakoff S. Induction of virus specific H-2 restricted murine CTL by liposomes. *In*: Vitetta E, Bach F, Bonavida B, eds. T and B cell recognition. New York Academic Press, 1979: 623-32.
2. Greene MJ, Bromberg JS, Nepom J, Finberg RW, Rock K, Whitaker B, Germain RN, Fox I, Perry L, Wetzig R, Takaoki M, Nisonoff A, Benacerraf B, Sy MS. The role of idiotypes in guiding cellular responses. *In*: Janeway C, Sercarz E, Wigzell H, eds. Immunoglobulin idiotypes and their expression. New York Academic Press, 1981: 725-9.
3. Schatten S, Drebin JA, Takaoki M, Carter R, Tominaga A, Abbas AR, Finberg RW, Greene MJ. Regulation of the immune response to cell surface antigens in ICN. UCLA Symposium. New York Academic Press, 1982: 95-100.
4. Nadler LM, Takvorian T, Botnick L, Bast RC Jr, Finberg R, Hellman S, Canellos GP, Schlossman SF. In vitro treatment with B1 monoclonal antibody prior to autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. *In*: Meischer PA, ed. Immunopharmacology. Seronc Symposia, Number 23. New York: Raven Press, 1985: 129-38.
5. Finberg RW. New approaches to immunization against infectious agents: Use of anti-idiotypic antibodies. *In*: Cruse JM, Lewis RE, eds. The Year in Immunology 1984-85. Basel: Karger, 1985: 175-81.
6. Ertl HCJ, McCarthy E, Homans E, Finberg RW. Induction of antiviral immune response by anti-idiotypic antibody directed against a sendai virus-specific murine T-helper-cell clone. *In*: Dreesman GR, Bronson JG, Kennedy RC, eds. High Technology Route to Virus Vaccines. American Society for Microbiology, Washington, D.C. 1985: 125.
7. Finberg RW. Newly defined infectious disease problems: Lyme disease, babesiosis, AIDS, and toxic shock syndrome. *In*: Branch WR, Jr., ed. Office Practice of Medicine. Philadelphia: WB Saunders, 1987: 1112-24.
8. Antman K, Peters WP, Eder JP, Schryber S, Andersen J, Henner WD, Elias A, Shea T, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Come S, Gorgone B, Bast RC Jr, Schnipper L, Frei E III. Treatment of 58 patients on a phase I and II protocol using a high dose combination alkylating agent preparation regimen with autologous bone marrow support. *In*: Fortner JG, Rhodes JE, eds. Accomplishments in Cancer Research, 1986. Philadelphia and Toronto: J.B. Lippincott Co., 1987: 152-65.
9. Antman K, Eder JP, Elias A, Shea T, Schryber S, Andersen J, Peters WP, Henner WD, Finberg R, Wilmore D, Kaplan W, Lew M, Kruskall MS, Anderson K, Bast RC Jr, Schnipper L, Frei E III. A preparative regimen of combination alkylating agent with autologous bone marrow transplant (AMBT) for solid tumors phase II. *In*: Gale RP, Champlin R, eds. 1986 UCLA Symposia Proceedings: Progress in Bone Marrow Transplantation. New York: Alan R. Liss, Inc., 1987: 855-64.
10. Kasper DL, Finberg RW. The bacteria. *In*: Samter M, Talmage DW, Frank MM, Austen KF, Claman HN, eds. Immunological Diseases, Fourth Edition. Boston: Little, Brown and Co., 1988: 803-32.
11. Ertl HCJ, Woo L, Finberg RW. Induction of a cellular immune response by an anti-idiotypic antibody. *In*: Zanetti M, ed. International Conference: Idiotypes and Diseases. Academic Press, 1988: 269-81.

12. Ertl HCJ, Woo L, Finberg RW. Immunogenicity of an anti-idiotypic directed to a Sendai virus specific T cell clone. In: Mohn JF, ed. 10th International Convocation on Immunology. Basel: Karger, 1988.
13. Ertl HCJ, Woo L, Finberg RW. Modulation of the immune response by anti-idiotypic antibodies with specificity for B or T cell idiotypes. In: Bona C, ed. Elicitation and use of anti-idiotypic antibodies and their biological applications. Basel: Karger, 1989.
14. Finberg RW. New concepts in the interaction between T cells and bacteria. In: Cruse JM, Lewis RE Jr, eds. The Year in Immunology. Molecules and Cells of Immunity. Year Immunol. Basel: Karger, 1990; 6:140-51.
15. Finberg RW, Weinstein L. Abscess of the lung. In: Feigen RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases, Third Edition. Philadelphia: WB Saunders Company, 1992: 320-5.
16. Finberg RW. Infections in the immunocompromised host. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th Edition. New York: McGraw-Hill Inc., 1994; chap 96, pp. 572-583.
17. Finberg RW. Infection in the patient with neoplastic disease. In Macdonald JS, Haller DG, Mayer RJ, eds. Manual of Oncologic Therapeutics. Philadelphia: J.B. Lippincott Company, 1995;chap. 59, pp. 415-429.
18. Finberg RW. Infection in Cancer Patients. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th Edition. New York: McGraw-Hill Inc., 1997; chap 87, pp. 537-543.
19. Finberg RW, Fingerroth, JD. Infection in Transplant Receipients. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th Edition. New York: McGraw-Hill Inc., 1997; Chap 136, pp. 840-846.
20. Finberg RW, Connor M. Infection Control in Cancer Patients and Bone Marrow Transplant Recipients. In: Abrutyn E. Saunders Infection Control Reference Service. Philadelphia: W.B. Saunders, 1997, pp 625-630.

Proceeding of Meetings:

1. Finberg RW, Ertl HCJ. Use of anti-idiotypic antibodies as immunizing antigens. In: Ginsberg H, Brown F, Lerner RA, Chanock RM, eds. Vaccines 87: New chemical and genetic approaches to vaccination: prevention of AIDS and other viral, bacterial and parasitic diseases. Cold Spring Harbor Laboratory, New York. 1987: 7-11.
2. Finberg R, Haregewoin A, Bergelson J, Crabb J, Kasper D, Onderdonk A. Use of T-cell hybridoma products to prevent bacterial disease. In: Ginsberg H, Brown F, Lerner RA, Chanock RM, eds. Vaccines 88: New chemical and genetic approaches to vaccination: prevention of AIDS and other viral, bacterial, and parasitic diseases. Cold Spring Harbor Laboratory, New York. 1988: 121-6.
3. Solomon KR, Chan M, Finberg RW. The expression of GPI-linked molecules on CD56+ NK cells. In: Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF, eds. Boston: Proceedings of the Fifth International Workshop and Conference on Human Leukocyte Differentiation Antigens, 1995;AS.1.12:1492

Case Reports:

1. Finberg RW, Richardson EP, Mark EJ. CPC, Massachusetts General Hospital : A 53 year old man with fever and rapid neurologic deterioration. N Engl J Med 1984; 311(24):1559-66.
2. Finberg, RW, Mattia, AR. CPC, Massachusetts General Hospital: A 47-Year old man with inguinal lymphadenopathy and fever during preparation for a bone marrow transplant. N Engl J Med 1994;331(25):1703-09.

vid glück! All virus received from Dr. David Knipe.

① Injection mice with:

① ICP₈ 10^6 pfu $n = 8$ Balb

ICP₈ stock d301 (received from Dr. David Knipe's Lab (Kay) on today)

1.7×10^9 pfu / cc \Rightarrow 17×10^8 pfu / cc.
Need 10^6 pfu / cc.

so do: a 1: 1700 Dilution
that means: 100 λ in 170000 = 170 cc
(virus stock)

or: 100 λ in 85 cc PBS
and injection of 5 cc ICP₂₇ (504 6.10⁸)

② ICP₂₇: ($n = 504$ R) 4×10^8 pfu/cc
 $n = 8$

Need 10^6 pfu / cc: Balb mice.

So do: a 1: 4×10^2 Dilution
that means 100 λ in 40000 = 40 cc PBS
(virus)

or 100 λ in 20 cc
and inject 0.5 cc. 20 cc

③ ICP₄: (received from Dr. Neal de Luca)

5.5×10^9 pfu / cc.
 \approx Need 100 λ then do a
1: $5.5 \times 10^2 = 550$ Dilution

Experiment:

(2) Bell mice / c Antac ♀.
5-7 weeks by

Challenged			\bar{c}	
10^6 pfu	HSV	ICP ₄	$n = 8$	(2)
10^6 pfu	HSV	ICP ₈	$n = 8$	(2)
10^6 pfu	HSV	ICP ₂₇	$n = 8$	(3)
and			$n = 9$	(4)
PBS	as	Control		

1. Bleeding
2. Bleeding

Challenge \bar{c} 10^8 pfu

HSV - mp.
Mortality:
in 10 days

(2) (ICP₄)

2 died / from 6. ^{total}
(2 for proliferation assay)

(2) (ICP₈)

0 died.

(3) (ICP₂₇)

0 died.

(4)

8 died from 9. (Control)

H003497